article · BMJ Neurology Open

An updated systematic review and meta-analysis exploring the efficacy and safety of dimethyl fumarate (DMF) for patients with multiple sclerosis (MS)

Hossam Tharwat Ali
Hazem Khaled Hassaan
Dalia Atef Abouda
Amr Mahmoud Yousef
Amr El‐Sayed
A. Mahmoud
Sara Hosny El-Farargy
Ahmed Mohamed Abdelmonhem
Ahmed M. Afifi

20243 citationsOpen accessBenha University

Abstract

DMF had significant efficacy and safety compared with the control, with no difference between the DMF doses. More studies with large sample sizes and longer follow-ups are needed to detect long-term safety and efficacy.

Research topics

Multiple Sclerosis Research Studies
Polyomavirus and related diseases
Mycobacterium research and diagnosis

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1136/bmjno-2024-000872

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.